.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
AstraZeneca
Cipla
Healthtrust
Baxter
Dow
Fuji
Fish and Richardson
Julphar
UBS

Generated: December 13, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,258,132

« Back to Dashboard

Which drugs does patent 8,258,132 protect, and when does it expire?


Patent 8,258,132 protects EMEND and is included in two NDAs. There have been four Paragraph IV challenges on Emend.

This patent has forty patent family members in thirty-five countries.

Summary for Patent: 8,258,132

Title:Pharmaceutical composition of a tachykinin receptor antagonist
Abstract: The present invention is directed to novel pharmaceutical compositions of the compound 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluoro)phen- yl-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methylmorpholine. The pharmaceutical compositions of this invention useful in the treatment or prevention of disorders such as psychiatric disorders including depression and anxiety, inflammatory diseases and emesis.
Inventor(s): Bosch; H. William (Bryn Mawr, PA), Liversidge; Elaine (West Chester, PA), Shelukar; Suhas D. (Lansdale, PA), Thompson; Karen C. (Lansdale, PA)
Assignee: Merck Sharp & Dohme Corp. (Rahway, NJ)
Application Number:10/317,948
Patent Claim Types:
see list of patent claims
Composition; Compound; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
MerckEMENDaprepitantCAPSULE;ORAL021549-003Jun 30, 2006ABRXYesNo► Subscribe► Subscribe► SubscribeYFOR THE PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH CHEMOTHERAPY
MerckEMENDaprepitantCAPSULE;ORAL021549-003Jun 30, 2006ABRXYesNo► Subscribe► Subscribe► SubscribeYPREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING
MerckEMENDaprepitantCAPSULE;ORAL021549-001Mar 26, 2003ABRXYesNo► Subscribe► Subscribe► SubscribeYPREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING
MerckEMENDaprepitantCAPSULE;ORAL021549-001Mar 26, 2003ABRXYesNo► Subscribe► Subscribe► SubscribeYFOR THE PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH CHEMOTHERAPY
MerckEMENDaprepitantCAPSULE;ORAL021549-002Mar 26, 2003ABRXYesYes► Subscribe► Subscribe► SubscribeYFOR THE PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH CHEMOTHERAPY
MerckEMENDaprepitantCAPSULE;ORAL021549-002Mar 26, 2003ABRXYesYes► Subscribe► Subscribe► SubscribeYPREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING
Msd Merck CoEMENDaprepitantFOR SUSPENSION;ORAL207865-001Dec 17, 2015RXYesYes► Subscribe► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,258,132

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada2469315► Subscribe
China1617712► Subscribe
China100352443► Subscribe
Colombia5590887► Subscribe
Germany60227556► Subscribe
Denmark1455756► Subscribe
Dominican RepublicP2002000542► Subscribe
Eurasian Patent Organization200400794► Subscribe
Eurasian Patent Organization007332► Subscribe
EcuadorSP045144► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Julphar
Covington
McKinsey
Teva
US Army
Healthtrust
Harvard Business School
Federal Trade Commission
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot